Molecular breeding of allergy vaccines and antiallergic cytokines

International Archives of Allergy and Immunology

Volumn 121, Issue 3, 2000, Pages 173-182

  Punnonen, Juha ^a  

^a Maxygen   (United States)

Author keywords

Allergy vaccines; Cytokines; DNA shuffling; IgE; Immunotherapy; Molecular breeding

Indexed keywords

ALLERGEN; ALPHA INTERFERON; ANTIALLERGIC AGENT; CYTOKINE; DNA; DNA VACCINE; IMMUNOGLOBULIN E;

ALLERGY; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0034061669     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024315     Document Type: Review

References (85)

1. Stemmer WP: Rapid evolution of a protein in vitro by DNA shuffling. Nature 1994;370:389-391.
2. Stemmer WP: DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution. Proc Natl Acad Sci USA 1994;91:10747-10751.
3. Crameri A, Raillard SA, Bermudez E, Stemmer WP: DNA shuffling of a family of genes from diverse species accelerates directed evolution. Nature 1998;391:288-291.
4. Cadwell RC, Joyce GF: Randomization of genes by PCR mutagenesis. PCR Methods Appl 1992;2:28-33.
5. Gram H, Marconi LA, Barbas CFD, Collet TA, Lerner RA, Kang AS: In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci USA 1992;89:3576-3580.
6. Saviranta P, Pajunen M, Jauria P, Karp M, Pettersson K, Mantsala P, Lovgren T: Engineering the steroid-specificity of an anti-17beta-estradiol Fab by random mutagenesis and competitive phage panning. Protein Eng 1998;11:143-152.
7. Shibata H, Kato H, Oda J: Random mutagenesis on the Pseudomonas lipase activator protein, LipB: Exploring amino acid residues required for its function. Protein Eng 1998;11:467-472.
8. You L, Arnold FH: Directed evolution of subtilisin E in Bacillus subtilis to enhance total activity in aqueous dimethylformamide. Protein Eng 1996;9:77-83.
9. Arnold FH: Engineering proteins for nonnatural environments. FASEB J 1993;7:744-749.
10. Moore JC, Jin HM, Kuchner O, Arnold FH: Strategies for the in vitro evolution of protein function: Enzyme evolution by random recombination of improved sequences. J Mol Biol 1997;272:336-347.
11. Christians FC, Scapozza L, Crameri A, Folkers G, Stemmer WP: Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. Nat Biotechnol 1999;17:259-264.
12. Ness JE, Welch M, Giver L, Bueno M, Cherry JR, Borchert TV, Stemmer WP, Minshull J: DNA shuffling of subgenomic sequences of subtilisin. Nat Biotechnol 1999;17:893-896.
13. Chang CC, Chen TT, Cox BW, Dawes GN, Stemmer WP, Punnonen J, Patten PA: Evolution of a cytokine using DNA family shuffling. Nat Biotechnol 1999;17:793-797.
14. Zurawski SM, Vega F Jr. Huyghe B, Zurawski G: Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993;12:2663-2670.
15. Kruse N, Tony HP, Sebald W: Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J 1992;11:3237-3244.
16. Aversa G, Punnonen J, Cocks BG, de Waal Malefyt R, Vega F Jr, Zurawski SM, Zurawski G, de Vries JE: An interleukin 4 (IL-4) mutant portein inhibits both IL-4-or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: Support for a common component shared by IL-4 and IL-13 receptors. J Exp Med 1993;178:2213-2218.
17. Punnonen J, Carballido JM, Aversa G, Cocks BG, de Vries JE: Inhibition of human IgE synthesis by an IL-4/IL-13 receptor antagonist in vitro and in vivo; in Basomba A, Sastre J (eds): Proceedings of 16th European Congress of Allergology and Clinical Immunology I. Bologna, Monduzzi, 1995, pp 29-36.
18. Carballido JM, Aversa G, Schols D, Punnonen J, de Vries JE: Inhibition of human IgE synthesis in vitro and in SCID-hu mice by an interleukin-4 receptor antagonist. Int Arch Allergy Immunol 1995;107:304-307.
19. Carballido JM, Schols D, Namikawa R, Zurawski S, Zurawski G, Roncarolo MG, de Vries JE: IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice. Inhibition of ongoing IgE production by in vivo treatment with an IL-4/IL-13 receptor antagonist. J Immunol 1995;155:4162-4170.
20. Grunewald SM, Werthmann A, Schnarr B, Klein CE, Brocker EB, Mohrs M, Brombacher F, Sebald W, Duschl A: An antagonistic IL-4 mutant prevents type 1 allergy in the mouse: Inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol 1998;160:4004-4009.
21. Crameri A, Whitehorn EA, Tate E, Stemmer WP: Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat Biotechnol 1996;16:315-319.
22. Crameri A, Cwirla S, Stemmer WP: Construction and evolution of antibody-phage libraries by DNA shuffling. Nat Med 1996;2:100-102.
23. Zhang JH, Dawes G, Stemmer WP: Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening. Proc Natl Acad Sci USA 1997;94:4504-4509.
24. Crameri A, Dawes G, Rodriguez E Jr, Silver S, Stemmer WP: Molecular evolution of an arsenate detoxification pathway by DNA shuffling. Nat Biotechnol 1997;15:436-438.
25. Soong NW, Nomura L, Dawes G, Stemmer WPC: Molecular breeding of viruses (submitted).
26. Coffman RL, Ohara J, Bond MW, Carty J, Zlotnik A, Paul WE: B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol 1986;136:4538-4541.
27. Pene J, Rousset F, Briere F, Chrétien I, Paliard X, Banchereau J, Spits H, De Vries JE: IgE production by normal human B cells induced by alloreactive T cell clones is mediated by IL-4 and suppressed by IFN-gamma. J Immunol 1988;141:1218-1224.
28. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, de Waal Malefyt R, de Vries JE: Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993;90:3730-3734.
29. Kiniwa M, Gately M, Gubler U, Chizzonite R, Fargeas C, Delespesse G: Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest 1992;90:262-266.
30. Punnonen J, de Vries JE: IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells. J Immunol 1994;152:1094-1102.
31. Finkelman FD, Madden KB, Cheever AW, Katona IM, Morris SC, Gately MK, Hubbard BR, Gause WC, Urban JF Jr: Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med 1994;179:1563-1572.
32. Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon S, Kastelein R, Bazan F, O'Garra A: IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997;7:571-581.
33. Hofstra CL, Van Ark I, Hofman G, Kool M, Nijkamp FP, Van Oosterhout AJ: Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J Immunol 1998;161:5054-5060.
34. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT: Allergen immunotherapy decreases intrleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-2130.
35. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-4194.
36. Benjaponpitak S, Oro A, Maguire P, Marinkovich V, DeKruyff RH, Umetsu DT: The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999;103:468-475.
37. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475.
38. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T, Makiguchi N, Suganuma T: Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984;72:955-962.
39. Shimada S, Yano O, Inoue H, Kuramoto E, Fukuda T, Yamamoto H, Kataoka T, Tokunaga T: Antitumor activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic moouse tumors. J Natl Cancer Inst 1985;74:681-688.
40. Yamamoto S, Kuramoto E, Shimada S, Tokunaga T: In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 1988;79:866-873.
41. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T: DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992;36:983-997.
42. Tokunaga T, Yano O, Kuramoto E, Kimura Y, Yamamoto T, Kataoka T, Yamamoto S: Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol 1992;36:55-66.
43. Kataoka T, Yamamoto S, Yamamoto T, Kuramoto E, Kimura Y, Yano O, Tokunaga T: Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG. Jpn J Cancer Res 1992;83:244-247.
44. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
45. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE: Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 1996;98:1119-1129.
46. Parronchi P, Brugnolo F, Annunziato F, Manuelli C, Sampognaro S, Mavilia C, Romagnani S, Maggi E: Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors. J Immunol 1999;163:5946-5953.
47. Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA: Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996;93:5141-5145.
48. Spiegelberg HL, Tighe H, Roman M, Broide D, Raz E: Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides. Allergy 1998;53:93-97.
49. Spiegelberg HL, Broide D, Tighe H, Roman M, Raz E: Inhibition of allergic inflammation in the lung by plasmid DNA allergen immunization. Pediatr Pulmonol Suppl 1999;18:118-121.
50. Slater JE, Paupore E, Zhang YT, Colberg-Poley AM: The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin Immunol 1998;102:469-475.
51. Wheeler AW, Drachenberg K-J: New routes and formulations for allergen-specific immunotherapy. Allergy 1997;52:602-612.
52. Durham SR, Till SJ: Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157-164.
53. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K: Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98-106.
54. Maggi E, Giudizi MG, Biagiotti R, Annunziato F, Manetti R, Piccinni MP, Parronchi P, Sampognaro S, Giannarini L, Zuccati G, Romagnani S: Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med 1994;180:489-495.
55. Noble A, Macary PA, Kenemy DM: IFN-gamma and IL-4 regulate the growth and differentiation of CD8+ T cells into subpopulations with distinct cytokine profiles. J Immunol 1995; 155:2928-2937.
56. Punnonen J, Yssel H, de Vries JE: The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells. J Allergy Clin Immunol 1997;100:792-801.
57. Holmes BJ, MacAry PA, Noble A, Kemeny DM: Antigen-specific CD8+ T cells inhibit IgE responses and interleukin-4 production by CD4+ T cells. Eur J Immunol 1997;27:2657-2665.
58. Ausubel LJ, Krieger JI, Hafler DA: Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99. J Immunol 1997;159:2502-2512.
59. Stemmer WPC, Soong NW: Molecular breeding of viruses for targeting and other clinical properties. Tumor Targeting 1999;4:59-62.
60. Momburg F, Roelse J, Howard JC, Butcher GW, Hämmerling GJ, Necfjes JJ: Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 1994;367:648-651.
61. Lauvau G, Kakimi K, Niedermann G, Ostankovitch M, Yotnda P, Firat H, Chisari FV, van Endert PM: Human transporters associated with antigen processing (TAPs) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells. J Exp Med 1999;190:1227-1240.
62. Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, Mori A, Okudaira H, Okumura Y: Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat Biotechnol 1997;15:754-758.
63. Nishiyama C, Yuuki T, Takai T, Okumura Y, Okudaira H: Determination of three disulfide bonds in a major house dust mite allergen. Der f II. Int Arch Allergy Immunol 1993;101:159-166.
64. Schramm G, Kahlert H, Suck R, Weber B, Stuwe HT, Muller WD, Bufe A, Becker WM, Schlaak MW, Jager L, Cromwell O, Fiebig H: 'Allergen engineering': Variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 1999;162:2406-2414.
65. Yasuc M, Yokota T, Fukada M, Takai T, Suko M, Okudaira H, Okumura Y: Hyposensitization to allergic reaction in rDer f 2-sensitized mice by the intranasal administration of a mutant of rDer f 2, C8/119S. Clin Exp Immunol 1998;113:1-9.
66. Punnonen J, de Vries JE: Cytokines and IgE regulation; in Denburg J (ed): Allergy and Allergic Diseases: The New Mechanisms and Therapeutics. Part I. Totowa, Humana Press, 1998, pp 13-40.
67. Yoshimoto T, Okamura H, Tagawa YI, Iwakura Y, Nakanishi K: Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci USA 1997;94:3948-3953.
68. Gauchat JF, Aversa G, Gascan H, de Vries JE: Modulation of IL-4 induced germline epsilon RNA synthesis in human B cells by tumor necrosis factro-alpha, anti-CD40 monoclonal antibodies or transforming growth factor-beta correlates with levels of IgE production. Int Immunol 1992;4:397-406.
69. Xu L, Rothman P: IFN-gamma represses epsilon germline transcription and subsequently down-regulates switch recombination to epsilon. Int Immunol 1994;6:515-521.
70. Punnonen J, Cocks BG, de Vries JE: IL-4 induces germ-line IgE heavy chain gene transcription in human fetal pre-B cells. Evidence for differential expression of functional IL-4 and IL-13 receptors during B cell ontogeny. J Immunol 1995:155:4248-4254.
71. Punnonen J, de Waal Malefyt R, van Vlasselaer P, Gauchat JF, de Vries JE: IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes. J Immunol 1993;151:1280-1289.
72. Kimata H, Yoshida A, Ishioka C. Lindley I, Mikawa H: Interleukin 8 (IL-8) selectively inhibits immunoglobulin E production induced by IL-4 in human B cells. J Exp Med 1992;176:1227-1231.
73. Kimata H, Yoshida A, Fujimoto M, Mikawa H: Effect of vasoactive intestinal peptide, somatostatin, and substance P on spontaneous IgE and IgG4 production in atopic patients. J Immunol 1993;150:4630-4640.
74. Carucci JA, Auci DL, Herrick CA, Durkin HG: Neuropeptide-mediated regulation of hapten-specific IgE responses in mice. I. Substance P-mediated isotype-specific suppression of BPO-specific IgE antibody-forming cell responses induced in vivo and in vitro. J Leukoc Biol 1995;57:110-115.
75. Akasaki M, Jardieu P, Ishizaka K: Immunosuppressive effects of glycosylation inhibiting factor on the IgE and IgG antibody response. J Immunol 1986;136:3172-3179.
76. Mikayama T, Nakano T, Gomi H, Nakagawa Y, Liu YC, Sato M, Iwamatsu A, Ishii Y, Weiser WY, Ishizaka K: Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor. Proc Natl Acad Sci USA 1993;90:10056-10060.
77. Coffman RL, Seymour BW, Hudak S, Jackson J, Rennick D: Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 1989;245:308-310.
78. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD: Interleukin-13: Central mediator of allergic asthma. Science 1998;282:2258-2261.
79. Grunig G, Warnock M, Wakil AE, Venkayya R, Brumacher F. Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB: Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-2263.
80. Rogge L, D'Ambrosio D, Biffi M, Penna G, Minetti LJ, Presky DH, Adorini L, Sinigaglia F: The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol 1998;161:6567-6574.
81. Murphy KM, Ouyang W, Szabo SJ, Jacobson NG, Guler ML, Gorham JD, Gubler U, Murphy TL: T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Curr Top Microbiol Immunol 1999;236:13-26.
82. Swieter M, Ghali WA, Rimmer C, Befus D: Interferon-alpha/beta inhibits IgE-dependent histamine release from rat mast cells. Immunology 1989;66:606-610.
83. Punnonen J, Punnonen K, Jansen CT, Kalimo K: Interferon (IFN)-alpha, IFN-gamma, interleukin (IL)-2, and arachidoni: acid metabolites modulate IL-4-induced IgE synthesis similarly in healthy persons and in atopic dermatitis patients. Allergy 1993;48:189-195.
84. Souillet G, Rousset F, de Vries JE: Alpha-interferon treatment of patients with hyper-IgE syndrome. Lancet 1989:i:1384.
85. Uze G, Lutfalla G, Mogensen KE: Alpha and beta interferons and their receptor and their frieds and relations. J Interferon Cytokine Res 1995;15:3-26.